Place of fixed-dose combination containing perindopril and indapamide in the treatment of arterial hipertension – hypertension specialist, diabetologist and cardiologist’s point of view Review article
Article Sidebar
Published:
Sep 30, 2017
Keywords:
arterial hypertension, pharmacotherapy, perindopril, indapamide
Main Article Content
Abstract
Hypertension is an important risk factor for cardiovascular complications, especially in highrisk groups. Despite the availability of many antihypertensive substances, it is often better to use combinations of several antihypertensive drugs. A composite of perindopril/indapamide has the potential of beneficial effect on the prognosis of patients at high cardiovascular risk, including the elderly, patients with metabolic syndrome and diabetes mellitus. The following article is the point of view of experts in the field of cardiology, hypertension and diabetes mellitus on the benefits of perindopril/indapamide combination in patients with hypertension and co-morbidities.
Article Details
How to Cite
Szymański , F. M., Prejbisz , A., & Dzida , G. (2017). Place of fixed-dose combination containing perindopril and indapamide in the treatment of arterial hipertension – hypertension specialist, diabetologist and cardiologist’s point of view. Medycyna Faktow (J EBM), 10(3(36), 246-250. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2133
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Aronow W.S., Fleg J.L., Pepine C.J. et al.: ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011; 123: 2434-2506.
2. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013; 31: 1281-1357.
3. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.
4. Emeriau J.P., Knauf H., Pujadas J.O. et al.: A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J. Hypertens. 2001; 19: 343-350.
5. Farsang C.: Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO trial. Adv. Ther. 2014; 31: 333-344.
6. Beckett N.S., Peters R., Fletcher A.E. et al.: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358: 1887-1898.
7. Peters R., Beckett N., Forette F. et al.: Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008; 7: 683-689.
8. Kim C.J., Kang H.S., Schlenk E.A., Chae S.M.: Assessment of cardiovascular risk in adults with type 2 diabetes and metabolic syndrome: Framingham versus UKPDS equations. Diabetes Educ. 2015; 41(2): 203-213.
9. 2017 Guidelines on the management of diabetic patients: A position of Diabetes Poland. Clin. Diabet. 2017; 6(supl. A): A1-A80.
10. Standards of Medical Care in Diabetes – 2017: Summary of Revisions. Diabetes Care 2017; 40(supl. 1): S4-S5.
11. ADVANCE Collaborative Group; Patel A., MacMahon S., Chalmers J. et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008; 358(24): 2560-2572.
12. Zoungas S., Chalmers J., Neal B. et al.; ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371(15): 1392-1406.
13. Reynolds K., He J.: Epidemiology of the metabolic syndrome. Am. J. Med. Sci. 2005; 330(6): 273-279.
14. Farsang C.: Skuteczność i tolerancja preparatu złożonego zawierającego peryndopryl i indapamid w cukrzycy typu 2 – badanie PICASSO. Adv. Ther. 2014; 31: 333-344.
15. Karnes J.H., Gong Y., Pacanowski M.A. et al.: Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet. Genomics. 2013; 23(12): 697-705.
16. Roush G.C., Ernst M.E., Kostis J.B. et al.: Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015; 65(5): 1041-1046.
2. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013; 31: 1281-1357.
3. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.
4. Emeriau J.P., Knauf H., Pujadas J.O. et al.: A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J. Hypertens. 2001; 19: 343-350.
5. Farsang C.: Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO trial. Adv. Ther. 2014; 31: 333-344.
6. Beckett N.S., Peters R., Fletcher A.E. et al.: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358: 1887-1898.
7. Peters R., Beckett N., Forette F. et al.: Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008; 7: 683-689.
8. Kim C.J., Kang H.S., Schlenk E.A., Chae S.M.: Assessment of cardiovascular risk in adults with type 2 diabetes and metabolic syndrome: Framingham versus UKPDS equations. Diabetes Educ. 2015; 41(2): 203-213.
9. 2017 Guidelines on the management of diabetic patients: A position of Diabetes Poland. Clin. Diabet. 2017; 6(supl. A): A1-A80.
10. Standards of Medical Care in Diabetes – 2017: Summary of Revisions. Diabetes Care 2017; 40(supl. 1): S4-S5.
11. ADVANCE Collaborative Group; Patel A., MacMahon S., Chalmers J. et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008; 358(24): 2560-2572.
12. Zoungas S., Chalmers J., Neal B. et al.; ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371(15): 1392-1406.
13. Reynolds K., He J.: Epidemiology of the metabolic syndrome. Am. J. Med. Sci. 2005; 330(6): 273-279.
14. Farsang C.: Skuteczność i tolerancja preparatu złożonego zawierającego peryndopryl i indapamid w cukrzycy typu 2 – badanie PICASSO. Adv. Ther. 2014; 31: 333-344.
15. Karnes J.H., Gong Y., Pacanowski M.A. et al.: Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet. Genomics. 2013; 23(12): 697-705.
16. Roush G.C., Ernst M.E., Kostis J.B. et al.: Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015; 65(5): 1041-1046.